The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies:a meta-analysis
Abstract Background Chimeric antigen receptor T (CAR T) cells immunotherapy is rapidly developed in treating cancers, especially relapsed or refractory B-cell malignancies. Methods To assess the efficacy and safety of CAR T therapy, we analyzed clinical trials from PUBMED and EMBASE. Results Results...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2018-09-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12885-018-4817-4 |
| _version_ | 1818435582428184576 |
|---|---|
| author | Hui Zhou Yuling Luo Sha Zhu Xi Wang Yunuo Zhao Xuejin Ou Tao Zhang Xuelei Ma |
| author_facet | Hui Zhou Yuling Luo Sha Zhu Xi Wang Yunuo Zhao Xuejin Ou Tao Zhang Xuelei Ma |
| author_sort | Hui Zhou |
| collection | DOAJ |
| description | Abstract Background Chimeric antigen receptor T (CAR T) cells immunotherapy is rapidly developed in treating cancers, especially relapsed or refractory B-cell malignancies. Methods To assess the efficacy and safety of CAR T therapy, we analyzed clinical trials from PUBMED and EMBASE. Results Results showed that the pooled response rate, 6-months and 1-year progression-free survival (PFS) rate were 67%, 65.62% and 44.18%, respectively. We observed that received lymphodepletion (72% vs 44%, P = 0.0405) and high peak serum IL-2 level (85% vs 31%, P = 0.04) were positively associated with patients’ response to CAR T cells. Similarly, costimulatory domains (CD28 vs CD137) in second generation CAR T was positively associated with PFS (52.69% vs 33.39%, P = 0.0489). The pooled risks of all grade adverse effects (AEs) and grade ≥ 3 AEs were 71% and 43%. Most common grade ≥ 3 AEs were fatigue (18%), night sweats (14%), hypotension (12%), injection site reaction (12%), leukopenia (10%), anemia (9%). Conclusions In conclusion, CAR T therapy has promising outcomes with tolerable AEs in relapsed or refractory B-cell malignancies. Further modifications of CAR structure and optimal therapy strategy in continued clinical trials are needed to obtain significant improvements. |
| first_indexed | 2024-12-14T16:55:10Z |
| format | Article |
| id | doaj.art-dc0adfa7419349deb90fb6bc161f7e3f |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-12-14T16:55:10Z |
| publishDate | 2018-09-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-dc0adfa7419349deb90fb6bc161f7e3f2022-12-21T22:53:58ZengBMCBMC Cancer1471-24072018-09-0118111310.1186/s12885-018-4817-4The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies:a meta-analysisHui Zhou0Yuling Luo1Sha Zhu2Xi Wang3Yunuo Zhao4Xuejin Ou5Tao Zhang6Xuelei Ma7State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation CenterState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation CenterState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation CenterState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation CenterState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation CenterState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation CenterState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation CenterState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation CenterAbstract Background Chimeric antigen receptor T (CAR T) cells immunotherapy is rapidly developed in treating cancers, especially relapsed or refractory B-cell malignancies. Methods To assess the efficacy and safety of CAR T therapy, we analyzed clinical trials from PUBMED and EMBASE. Results Results showed that the pooled response rate, 6-months and 1-year progression-free survival (PFS) rate were 67%, 65.62% and 44.18%, respectively. We observed that received lymphodepletion (72% vs 44%, P = 0.0405) and high peak serum IL-2 level (85% vs 31%, P = 0.04) were positively associated with patients’ response to CAR T cells. Similarly, costimulatory domains (CD28 vs CD137) in second generation CAR T was positively associated with PFS (52.69% vs 33.39%, P = 0.0489). The pooled risks of all grade adverse effects (AEs) and grade ≥ 3 AEs were 71% and 43%. Most common grade ≥ 3 AEs were fatigue (18%), night sweats (14%), hypotension (12%), injection site reaction (12%), leukopenia (10%), anemia (9%). Conclusions In conclusion, CAR T therapy has promising outcomes with tolerable AEs in relapsed or refractory B-cell malignancies. Further modifications of CAR structure and optimal therapy strategy in continued clinical trials are needed to obtain significant improvements.http://link.springer.com/article/10.1186/s12885-018-4817-4Chimeric antigen receptor T (CAR T) therapySafetyEfficacyRelapsed or refractory B-cell malignancies |
| spellingShingle | Hui Zhou Yuling Luo Sha Zhu Xi Wang Yunuo Zhao Xuejin Ou Tao Zhang Xuelei Ma The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies:a meta-analysis BMC Cancer Chimeric antigen receptor T (CAR T) therapy Safety Efficacy Relapsed or refractory B-cell malignancies |
| title | The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies:a meta-analysis |
| title_full | The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies:a meta-analysis |
| title_fullStr | The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies:a meta-analysis |
| title_full_unstemmed | The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies:a meta-analysis |
| title_short | The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies:a meta-analysis |
| title_sort | efficacy and safety of anti cd19 cd20 chimeric antigen receptor t cells immunotherapy in relapsed or refractory b cell malignancies a meta analysis |
| topic | Chimeric antigen receptor T (CAR T) therapy Safety Efficacy Relapsed or refractory B-cell malignancies |
| url | http://link.springer.com/article/10.1186/s12885-018-4817-4 |
| work_keys_str_mv | AT huizhou theefficacyandsafetyofanticd19cd20chimericantigenreceptortcellsimmunotherapyinrelapsedorrefractorybcellmalignanciesametaanalysis AT yulingluo theefficacyandsafetyofanticd19cd20chimericantigenreceptortcellsimmunotherapyinrelapsedorrefractorybcellmalignanciesametaanalysis AT shazhu theefficacyandsafetyofanticd19cd20chimericantigenreceptortcellsimmunotherapyinrelapsedorrefractorybcellmalignanciesametaanalysis AT xiwang theefficacyandsafetyofanticd19cd20chimericantigenreceptortcellsimmunotherapyinrelapsedorrefractorybcellmalignanciesametaanalysis AT yunuozhao theefficacyandsafetyofanticd19cd20chimericantigenreceptortcellsimmunotherapyinrelapsedorrefractorybcellmalignanciesametaanalysis AT xuejinou theefficacyandsafetyofanticd19cd20chimericantigenreceptortcellsimmunotherapyinrelapsedorrefractorybcellmalignanciesametaanalysis AT taozhang theefficacyandsafetyofanticd19cd20chimericantigenreceptortcellsimmunotherapyinrelapsedorrefractorybcellmalignanciesametaanalysis AT xueleima theefficacyandsafetyofanticd19cd20chimericantigenreceptortcellsimmunotherapyinrelapsedorrefractorybcellmalignanciesametaanalysis AT huizhou efficacyandsafetyofanticd19cd20chimericantigenreceptortcellsimmunotherapyinrelapsedorrefractorybcellmalignanciesametaanalysis AT yulingluo efficacyandsafetyofanticd19cd20chimericantigenreceptortcellsimmunotherapyinrelapsedorrefractorybcellmalignanciesametaanalysis AT shazhu efficacyandsafetyofanticd19cd20chimericantigenreceptortcellsimmunotherapyinrelapsedorrefractorybcellmalignanciesametaanalysis AT xiwang efficacyandsafetyofanticd19cd20chimericantigenreceptortcellsimmunotherapyinrelapsedorrefractorybcellmalignanciesametaanalysis AT yunuozhao efficacyandsafetyofanticd19cd20chimericantigenreceptortcellsimmunotherapyinrelapsedorrefractorybcellmalignanciesametaanalysis AT xuejinou efficacyandsafetyofanticd19cd20chimericantigenreceptortcellsimmunotherapyinrelapsedorrefractorybcellmalignanciesametaanalysis AT taozhang efficacyandsafetyofanticd19cd20chimericantigenreceptortcellsimmunotherapyinrelapsedorrefractorybcellmalignanciesametaanalysis AT xueleima efficacyandsafetyofanticd19cd20chimericantigenreceptortcellsimmunotherapyinrelapsedorrefractorybcellmalignanciesametaanalysis |